肿瘤比例方案一线治疗同时伴有EGFR敏感突变和PD-L1高表达的转移性鳞状细胞肺癌1例报告

N. X, Xie H, Z. Z, Zou J
{"title":"肿瘤比例方案一线治疗同时伴有EGFR敏感突变和PD-L1高表达的转移性鳞状细胞肺癌1例报告","authors":"N. X, Xie H, Z. Z, Zou J","doi":"10.16966/2470-0991.265","DOIUrl":null,"url":null,"abstract":"A 56-year-old Asian male with 20 years smoking history was admitted to the hospital due to a cough with sputum production. Chest Computed Tomography (CT) revealed a tumor shadow in the right middle lung, and transbronchial biopsy diagnosed Lung Squamous Cell Carcinoma (LCSS). Further molecular pathological assessment detected Epidermal Growth Factor Receptor (EGFR) sensitive mutation, while Programmed Death-Ligand 1 (PD-L1) was highly expressed with a Tumor Proportion Score (TPS) of >70%. Tumor Proportion (TP) regime was the first-line of treatment gained an obvious reduction in tumor size. Until head progression was found, the patient took Osimertinib orally and is currently stable. Given the rarity of the LCSS with EGFR mutation and high-expressed PD-L1, this case report provides a successful clinical treatment option for doctors in similar situations.","PeriodicalId":115205,"journal":{"name":"Journal of Surgery: Open Access","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tumor Proportion Regime First-Line Therapy in Metastatic Squamous Cell Lung Cancer with both EGFR Sensitive Mutation and High PD-L1 Expression: A Case Report\",\"authors\":\"N. X, Xie H, Z. Z, Zou J\",\"doi\":\"10.16966/2470-0991.265\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A 56-year-old Asian male with 20 years smoking history was admitted to the hospital due to a cough with sputum production. Chest Computed Tomography (CT) revealed a tumor shadow in the right middle lung, and transbronchial biopsy diagnosed Lung Squamous Cell Carcinoma (LCSS). Further molecular pathological assessment detected Epidermal Growth Factor Receptor (EGFR) sensitive mutation, while Programmed Death-Ligand 1 (PD-L1) was highly expressed with a Tumor Proportion Score (TPS) of >70%. Tumor Proportion (TP) regime was the first-line of treatment gained an obvious reduction in tumor size. Until head progression was found, the patient took Osimertinib orally and is currently stable. Given the rarity of the LCSS with EGFR mutation and high-expressed PD-L1, this case report provides a successful clinical treatment option for doctors in similar situations.\",\"PeriodicalId\":115205,\"journal\":{\"name\":\"Journal of Surgery: Open Access\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Surgery: Open Access\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.16966/2470-0991.265\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgery: Open Access","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.16966/2470-0991.265","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

56岁亚裔男性,吸烟20年,因咳嗽含痰入院。胸部CT示右中肺肿瘤影,经支气管活检诊断为肺鳞状细胞癌。进一步的分子病理学检查发现表皮生长因子受体(EGFR)敏感突变,程序性死亡配体1 (PD-L1)高表达,肿瘤比例评分(TPS) >70%。肿瘤比例(TP)方案是一线治疗获得肿瘤大小明显减少。在发现头部进展前,患者口服奥西替尼,目前病情稳定。鉴于EGFR突变和高表达PD-L1的LCSS的罕见性,本病例报告为类似情况的医生提供了一个成功的临床治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Tumor Proportion Regime First-Line Therapy in Metastatic Squamous Cell Lung Cancer with both EGFR Sensitive Mutation and High PD-L1 Expression: A Case Report
A 56-year-old Asian male with 20 years smoking history was admitted to the hospital due to a cough with sputum production. Chest Computed Tomography (CT) revealed a tumor shadow in the right middle lung, and transbronchial biopsy diagnosed Lung Squamous Cell Carcinoma (LCSS). Further molecular pathological assessment detected Epidermal Growth Factor Receptor (EGFR) sensitive mutation, while Programmed Death-Ligand 1 (PD-L1) was highly expressed with a Tumor Proportion Score (TPS) of >70%. Tumor Proportion (TP) regime was the first-line of treatment gained an obvious reduction in tumor size. Until head progression was found, the patient took Osimertinib orally and is currently stable. Given the rarity of the LCSS with EGFR mutation and high-expressed PD-L1, this case report provides a successful clinical treatment option for doctors in similar situations.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信